Crohn's Disease

In a commentary published in Gastroenterology, experts propose initiatives that aim to increase diversity in inflammatory bowel disease clinical trials.

Among patients with inflammatory bowel disease who received at least two biologic therapies, discontinuation of treatment appeared to vary based on initial treatment choice, according to data presented at the ACG Annual Scientific Meeting.

LAS VEGAS – Patients dosed with Skyrizi for Crohn’s disease achieved clinical remission, endoscopic response and persistent improvements to inflammatory biomarkers consistent with a dose-response relationship.

LAS VEGAS — Inflammatory bowel disease clinical trials underrepresent racial and ethnic minority groups, according to a presentation at the ACG Annual Scientific Meeting.

LAS VEGAS — In this video exclusive, Paul Feuerstadt, MD, FACG, AGAF, discussed a study assessing the investigational live microbiota-based biotherapeutic, RBX2660 for the treatment of Clostridioides difficile, at the ACG Annual Scientific Meeting.

LAS VEGAS – In this video exclusive, Miguel Regueiro, MD, discussed a study assessing the risk of severe disease in postoperative patients with Crohn’s disease with isolated anastomotic disease.

Higher ustekinumab trough concentration levels correlated with increased rates of endoscopic remission among patients with Crohn’s disease, according to research published in BMC Gastroenterology.

Patients with pediatric onset inflammatory bowel disease may have a higher risk for cancer and death, according to a presentation at UEG Week Virtual 2021.

In a video exclusive, Subrata Ghosh, MD, of the University College Cork, reported older patients with inflammatory bowel disease treated with Stelara did not experience increased rates of serious adverse events compared with placebo.

Among pediatric patients with Crohn’s disease and ulcerative colitis, the risk for incidence of intestinal resection and colectomy after 5 years of diagnosis decreased over a 24-year period, according to a presenter at UEG Week.